Evidence map›Paper›PMID 24629717›Full record

ArticleBiological psychiatry2014

Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5.

Laura Glück, Anastasia Loktev, Lionel Moulédous, Catherine Mollereau, Ping-Yee Law, Stefan Schulz

Abstract read
In one paragraph

Article in Biological psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Genetic mouse models in opioid research: current status and future directions.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. A cellular perspective of bias at G protein-coupled receptors.Protein science : a publication of the Protein Society · 2020
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Laura GlückInstitute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
Anastasia LoktevInstitute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany.
Lionel MoulédousInstitut de Pharmacologie et de Biologie Structurale, CNRS/Université de Toulouse, Toulouse Cedex, France.
Catherine MollereauInstitut de Pharmacologie et de Biologie Structurale, CNRS/Université de Toulouse, Toulouse Cedex, France.
Ping-Yee LawDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota.
Stefan SchulzInstitute of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany. Electronic address: Stefan.Schulz@med.uni-jena.de.
Friedrich Schiller University Jena · DEUniversity of Minnesota Medical Center · US

Funding

Studies on the the mechanism of OPRM1 biased agonism and in vivo consequences: DiR01DA031442 · NIDA · UNIVERSITY OF MINNESOTA · PI LAW, PING-YEE · 2012 to 2016
$1.9M
NIDA NIH HHS 1R01DA031442-01A1NIDA NIH HHS R01 DA031442
6 · The paper itself

Abstract

backgroundThe clinical benefits of opioid drugs are counteracted by the development of tolerance and addiction. We provide in vivo evidence for the involvement of G protein-coupled receptor kinases (GRKs) in opioid dependence in addition to their roles in agonist-selective mu-opioid receptor (MOR) phosphorylation.

methodsIn vivo MOR phosphorylation was examined by immunoprecipitation and nanoflow liquid chromatography-tandem mass spectrometry analysis. Using the hot-plate and conditioned place preference test, we investigated opioid-related antinociception and reward effects in mice lacking GRK3 or GRK5.

resultsEtonitazene and fentanyl stimulated the in vivo phosphorylation of multiple carboxyl-terminal phosphate acceptor sites, including threonine 370, serine 375, and threonine 379, which was predominantly mediated by GRK3. By contrast, morphine promoted a selective phosphorylation of serine 375 that was predominantly mediated by GRK5. In contrast to GRK3 knockout mice, GRK5 knockout mice exhibited reduced antinociceptive responses after morphine administration and developed morphine tolerance similar to wild-type mice but fewer signs of physical dependence. Also, morphine was ineffective in inducing conditioned place preference in GRK5 knockout mice, whereas cocaine conditioned place preference was retained. However, the reward properties of morphine were evident in knock-in mice expressing a phosphorylation-deficient S375A mutation of the MOR.

conclusionsThese findings show for the first time that MOR phosphorylation is regulated by agonist-selective recruitment of distinct GRK isoforms that influence different opioid-related behaviors. Modulation of GRK5 function could serve as a new approach for preventing addiction to opioids, while maintaining the analgesic properties of opioid drugs at an effective level.

Indexed as

RewardAnalgesics, OpioidAnimalsBenzimidazolesConditioning, PsychologicalDrug ToleranceFentanylGene Knockout TechniquesG-Protein-Coupled Receptor Kinase 3G-Protein-Coupled Receptor Kinase 5MiceMice, KnockoutMorphineMorphine DependenceNociceptionPhosphorylationAnalgesics, OpioidBenzimidazolesetonitazeneFentanylG-Protein-Coupled Receptor Kinase 3G-Protein-Coupled Receptor Kinase 5GRK3 protein, mouseGrk5 protein, mouseMorphineProtein IsoformsReceptors, Opioid, muBar codeconditioned place preferencedependenceG protein–coupled receptor kinasemu opioid receptorphosphorylation

Identifiers

PMID24629717
PMCPMC4119866
OpenAlexW1964705194

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.